BioBusiness Asia 2017 examines global trends, new technologies shaping healthcare

BioBusiness Asia, the two-day business-themed life sciences conference held annually in Taipei, Taiwan, recently concluded. A part of the week-long BioTaiwan festival of life science-focused events, the conference this year had a wide range of session themes with a particular emphasis on emerging technologies such as precision medicine, next generation sequencing, artificial intelligence (AI), synthetic biology, cancer immunotherapy, and digital health.

Read more

AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera

AOP Orphan Pharmaceuticals AG of Vienna, Austria (AOP Orphan) and Taipei, Taiwan-headquartered PharmaEssentia Corporation (TPEx: 6446) together announced the latest results from three clinical studies on Ropeginterferon alfa-2b for patients with Polycythemia Vera (PV) presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain.

Read more

OBI Pharma announces acquisition of cancer drug candidate from Threshold Pharmaceuticals

Taipei, Taiwan-headquartered OBI Pharma, Inc., (TPex: 4174), announced last week that an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) had been made to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).

Read more